glp-1 agonist therapy Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH glp 1 signaling GLP-1R agonist

Plos One

As noted, the sequence similarity within the glucagon superfamily of peptides and the structural similarity within the secretin receptor family served as the molecular basis for engineering chimeric peptides with agonism at multiple receptors and with sizes comparable to the native peptides

Yet, some patients may not want to stay on injectable versions of GLP-1 weight loss drugs, such as semaglutide and tirzepatide, long term

This limits the affordability of many patients, especially from low- and middle-income groups and those who do not have medical insurance, restricting market growth

Whats more, exercise, including resistance training, can significantly reduce the risk of metabolic disease